Moreover, Morrow et al.’s investigation into IL6/JAK/STAT3 signaling in triple-negative breast cancer (TNBC) linked high expression of STAT3 in tumor-associated stroma with adverse clinical outcomes, reduced CD4+ T-cell infiltration, and increased tumor budding. This evidence concerns the gene STAT3 and neoplasm.